Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PellePharm, Inc.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.
Leo Sets Up For A David & Goliath Showdown In Atopic Dermatitis
Scrip talked to Leo Pharma's new CEO Catherine Mazzacco about going up against big biopharma players in dermatology and plans to file tralokinumab in 2020.
Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.